US EditionPublished • loading... • Updated
FDA Releases Guidance to Promote Nonopioid Alternatives for Chronic Pain
The FDA's draft guidance aims to increase non-opioid treatment development for chronic pain as opioids are prescribed to 20% of U.S. adults with chronic pain, officials said.
- On September 11, 2025, the FDA unveiled draft guidelines aimed at promoting effective non-opioid therapies for chronic pain and opened a 60-day period for public feedback.
- The guidance responds to the 2018 SUPPORT Act and ongoing opioid-related overdose deaths to expand alternatives amid continued opioid reliance.
- It outlines clinical trial design, patient selection, evaluation of non-opioid drugs’ ability to reduce opioid use, and expedited approval pathways.
- FDA Commissioner Marty Makary emphasized that the opioid crisis in the United States remains ongoing, highlighting that roughly 20% of adults with chronic pain continue to receive opioid prescriptions.
- The draft aims to stimulate non-opioid treatment development, building on January 2025 FDA approval of Journavx, the first non-opioid analgesic for acute pain.
Insights by Ground AI
34 Articles
34 Articles
The Norfolk Daily News+29 Reposted by 29 other sources
FDA Releases Guidance to Promote Nonopioid Alternatives for Chronic Pain
WEDNESDAY, Sept. 10, 2025 (HealthDay News) -- The U.S. Food and Drug Administration released draft guidance to advance safe and effective nonopioid treatment options and reduce risks tied to prescription opioid misuse.
Coverage Details
Total News Sources34
Leaning Left8Leaning Right5Center9Last UpdatedBias Distribution41% Center
Bias Distribution
- 41% of the sources are Center
41% Center
L 36%
C 41%
R 23%
Factuality
To view factuality data please Upgrade to Premium
